orbimed
(2)
Robert Jacks
Robert Jacks is President & CEO of Sparrow Pharmaceuticals, a Boston-based clinical-stage biopharmaceutical company developing targeted therapies for disorders driven by intracellular cortisol excess. In September 2025 he closed a $95 million Series B co-led by RA Capital and Forbion to advance clofutriben, an HSD-1 inhibitor, through a Phase 2b trial in type 2 diabetes patients with elevated cortisol. A civil engineer turned biotech operator, Jacks has spent 25 years in the industry, co-founded Symbiomix Therapeutics (sold after Solosec NDA approval), previously led Indalo Therapeutics, and has raised more than $300 million across his companies.
Matthew Loper
Matthew Loper is the co-founder and CEO of Wellth, a Los Angeles digital-health company that pays people small cash rewards for sticking to their care plans. A biological engineer from MIT turned healthcare banker and investor, he built Wellth around behavioral economics rather than technology - the idea that immediate, tangible incentives change what people actually do about their chronic conditions. Under his leadership Wellth has raised more than $73 million, including an oversubscribed $36 million Series C in 2025, and reports steep drops in hospital and emergency-room use among the high-need Medicare and Medicaid populations it serves.